Literature DB >> 2183642

Liver allograft rejection: an overview of morphologic findings.

A J Demetris1, S G Qian, H Sun, J J Fung.   

Abstract

Recent improvements in patient survival has resulted in widespread use of liver transplantation as therapy for end stage liver disease. The pathologist plays a critical role in the pre- and post-operative care of these patients, and the core needle biopsy of the allograft has become a fairly reliable method of diagnosing acute cellular rejection. Most of the non-rejection related causes of graft dysfunction produce morphologic manifestations similar to those seen in nontransplanted livers (e.g., duct obstruction resembles duct obstruction). Many pathologists are, however, unfamiliar with the histologic changes of the various types of rejection. The following article is an attempt to acquaint pathologists with the morphologic features of liver allograft rejection. As a backdrop to understanding the events in humans, observations in untreated experimental animals are presented and reviewed briefly.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2183642

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  13 in total

1.  Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection.

Authors:  A Zeevi; G Eiras; C Kaufman; M Alessiani; A J Demetris; K Abu-Elmagd; A Jain; V Warty; R Venkataramanan; G Burckart
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

2.  Recognition of major histocompatibility complex antigens on cultured human biliary epithelial cells by alloreactive lymphocytes.

Authors:  S L Saidman; R J Duquesnoy; A Zeevi; J J Fung; T E Starzl; A J Demetris
Journal:  Hepatology       Date:  1991-02       Impact factor: 17.425

3.  Use of prostaglandin E1 in crossmatch-negative liver transplant recipients treated with FK 506.

Authors:  S Takaya; O Bronsther; K Abu-Elmagd; H Ramos; J J Fung; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1993-06       Impact factor: 1.066

4.  Expression of vascular cell adhesion molecule (VCAM-1) in liver and pancreas allograft rejection.

Authors:  C E Bacchi; C L Marsh; J D Perkins; R L Carithers; J P McVicar; K L Hudkins; C D Benjamin; J M Harlan; R Lobb; C E Alpers
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

5.  Does the presence of a measurable blood alcohol level in a potential organ donor affect the outcome of liver transplantation?

Authors:  T I Hassanein; J S Gavaler; D Fishkin; R Gordon; T E Starzl; D H Van Thiel
Journal:  Alcohol Clin Exp Res       Date:  1991-03       Impact factor: 3.455

Review 6.  The liver allograft, chronic (ductopenic) rejection, and microchimerism: what can they teach us?

Authors:  A J Demetris; N Murase; C P Delaney; M Woan; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1995-02       Impact factor: 1.066

Review 7.  Aspects of liver transplant pathology with emphasis on rejection and its mechanisms.

Authors:  D G Wight
Journal:  J Clin Pathol       Date:  1994-04       Impact factor: 3.411

8.  Serum amyloid A protein (SAA): a marker for liver allograft rejection in humans.

Authors:  G Feussner; C Stech; J Dobmeyer; H Schaefer; G Otto; R Ziegler
Journal:  Clin Investig       Date:  1994-12

9.  The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors.

Authors:  S Takaya; O Bronsther; Y Iwaki; K Nakamura; K Abu-Elmagd; A Yagihashi; A J Demetris; M Kobayashi; S Todo; A G Tzakis
Journal:  Transplantation       Date:  1992-02       Impact factor: 4.939

10.  Induction of intercellular adhesion molecule-1 (CD54) on human hepatoma cell line HepG2: influence of cytokines and hepatitis B virus-DNA transfection.

Authors:  R Volpes; J J van den Oord; V J Desmet; S H Yap
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.